QURIENT THERAPEUTIC
Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model. Network R&D aims to capital efficient innovation, being able to tackle on new scientific innovations in various therapeutic areas through experts network.
QURIENT THERAPEUTIC
Social Links:
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2008-07-02
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.qurient.com
Total Employee:
11+
Status:
Active
Contact:
+82-31-8060-1600
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Tag Manager Apache Global Site Tag Mobile Non Scaleable Content Euro Google Apps For Business
Similar Organizations
Kyras Therapeutics
Kyras Therapeutics is a biotech company
Stock Details
Official Site Inspections
http://www.qurient.com Semrush global rank: 6.09 M Semrush visits lastest month: 1.33 K
- Host name: 211.43.212.55
- IP address: 211.43.212.55
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Qurient Therapeutic"
Qurient Therapeutic - Crunchbase Company Profile & Funding
Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in …See details»
Qurient Co., Ltd. (Qurient Co., Ltd.) - 药物管线_专利_临床试验_投融 …
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical …See details»
Qurient - Overview, News & Similar companies | ZoomInfo.com
Feb 2, 2023 Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent Landmark Agreement for New Tuberculosis …See details»
Qurient Co. Ltd. and TB Alliance Announce Exclusive License …
Feb 3, 2023 Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the …See details»
Qurient Company Profile - Office Locations, Competitors ... - Craft
Qurient has 3 employees at their 1 location and ₩9.03 b in annual revenue in FY 2023. See insights on Qurient including office locations, competitors, revenue, financials, executives, …See details»
Qurient Company Description - Stock Analysis
Nov 4, 2024 The company was formerly known as Quro Science Inc. and changed its name to Qurient Co., Ltd. in October 2011. Qurient Co., Ltd. was founded in 2008 and is headquartered …See details»
Qurient Co. Ltd. and TB Alliance Announce Exclusive License
Feb 3, 2023 Qurient is a clinical-stage biopharmaceutical company based in South Korea and is listed on the Korea Exchange (KRX 115180). Qurient focuses on the development of novel …See details»
Qurient Therapeutic - Contacts, Employees, Board Members
Qurient Therapeutic is a biotech company. Start Free Trial . Chrome ExtensionSee details»
Notice - Qurient
Qurient: 2023-12-15: 2393: 91 : 구주주 청약결과 및 일반공모 안내 : qurient: 2023-12-11: 2351: 열린 1 페이지; 2 페이지; 3 ...See details»
Pipeline - Qurient
Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs. Discovery Candidate Pre-Clinical Phase 1 Phase 2 Phase 3; Oncology Adrixetinib …See details»
Qurient Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Landmark Agreement for New Tuberculosis Treatment SEONGNAM-SI, South Korea and NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Qurient Co. Ltd. ("Qurient", KRX: 115180), a clinical …See details»
MPI of Biochemistry, LDC and Qurient Close License Deal on a …
Qurient works from discovery to human proof-of-concept programs, where transformation takes place from a high potential research program into a solid product portfolio. Further information …See details»
Original approach to multidrug- resistant tuberculosis - Nature
Www.qurient.com Figure 1: Scanning electron micrograph of Mycobacterium tuberculosis. Kiyean Nam, CEO Qurient Co., Ltd. Seongnam, Republic of Korea Tel: +82 31 8060 1600 Email: …See details»
Drug candidate for cancer immunotherapy enters Phase I study
May 27, 2020 For more info, please visit www.qurient.com. About the Lead Discovery Center. The Lead Discovery Center was established in 2008 by the technology transfer organization …See details»
Qurient Announces U.S. FDA Clearance of IND Application for …
May 26, 2020 Qurient receives U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy, and expects to start a Phase 1 clinical study 3Q2020. ... Lead Discovery …See details»
Qurient Announces U.S. FDA Clearance of IND Application for …
Feb 8, 2022 Qurient licensed the CDK7 inhibitor program at lead stage from Lead Discovery Center (LDC) and the Max-Planck Society and further optimized the program, completed the …See details»
Launch of Start-up QLi5 Therapeutics - Max Planck Innovation
Jun 16, 2020 Further information at: www.qurient.com. About Lead Discovery Center. The Lead Discovery Center was established in 2008 by the technology transfer organization Max Planck …See details»
First Patient Dosed in Phase 1 Study with Novel Anti-cancer ...
Qurient’s latest press release from January 26th, 2021 Qurient’s and LDC’s press release on IND approval from May 2020 # # # >> Contact ... Lead Disc overy Center GmbH was established …See details»
Welcome to Qurient Groupware System
Insert ID and Password.. ID Login: Password Copyright © 2015 Qurient Co., Ltd. All rights reserved.See details»